The Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) has carried out an assessment of spending on research across Europe, to add weight to its call for increased coordination.
The study, published in the The Lancet Infectious Diseases on 18 December, reported 1243 antibacterial resistance research projects funded in the EU. These received a total public investment of €1.3 billion, of which €646.6 million (49.5 per cent) was invested at the national level, and €659.2 million (50.5 per cent) at the EU level.
The study also reports a large variation between countries both in terms of the number and value of projects, and in terms of the prioritisation of R&D between the areas of therapeutics, diagnostics, surveillance, transmission, environment, and interventions. In light of the results, further joint programming activities are needed to help countries harmonise research activities and pool resources, the JPI said.